This may facilitate targeting DEP-1 in metabolic diseases without impairment of DEP-1 as a tumor suppressor protein, although neither spontaneous tumors were observed during DEP-1 ASO treatment in this study nor were described for DEP-1 KO mice [44]. This evidence concerns the gene PTPRJ and metabolic disease.